Anti-psoriasis fungus activity of paris polyphylla steroid saponin and application of paris polyphylla steroid saponin

Through the preparation and application of saponin A of the wrinkle leaves, the problems of long treatment process and major side effects of existing antifungal drugs have been solved, effective inhibition of fungi on the shallow skin is achieved, and new treatment plans and cosmetic ingredients are provided.

CN118955603AActive Publication Date: 2024-11-15KUNMING INST OF BOTANY CHINESE ACAD OF SCI
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
CN202410712085.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-06-04
Publication Date
2024-11-15
Estimated Expiration
2044-06-04

AI Technical Summary

Technical Problem

The existing antifungal drugs are used to treat superficial skin mycotic diseases, and the treatment process is long and the side effects are great. The antibacterial activities of Dulong Chonglou saponins A to D and saponins A are not reported, and there is a lack of effective new drug solutions.

Method used

Using a new compound, Crocodile saponin A (PFV92), the preparation method of Crocodile saponin A (PFV92) was prepared by extracting and separating Crocodile saponin, combined with silica gel column chromatography, thin layer chromatography and HPLC purification technology, Crocodile saponin was prepared A and use it as an active ingredient for the preparation of drugs and cosmetics for the prevention and treatment of superficial mycoses on the skin.

Benefits of technology

Saponin A of the waxy leaves significantly inhibits Trichophyton red, Epidermophyton flocculates and Microsporidium gypsum-like, providing new antibacterial activities, and for the first time its inhibitory effect on superficial fungi in the skin is reported, and can be used in cosmetics. Improves the effectiveness and safety of treating superficial skin mycotic diseases.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118955603A_ABST
    Figure CN118955603A_ABST
Patent Text Reader

Abstract

The invention provides a paris polyphylla saponin A compound as well as a pharmaceutical composition, a preparation method and application thereof, and belongs to the technical field of medicines and the technical field of cosmetics. The invention provides the paris polyphylla saponin A, and the application of the paris polyphylla saponin A-D and the paris polyphylla saponin A in preparation of medicines for preventing and treating skin superficial fungal diseases. The compound disclosed by the invention has a remarkable inhibition effect on dermatophyte such as trichophyton rubrum, epidermatophyton flocculent, microsporum gypsuum and the like, and can be used for preparing a medicine for preventing and treating skin superficial fungal diseases. The compound disclosed by the invention can be used for preparing a medicine for preventing and treating the skin superficial fungal diseases, and can be used for preparing a medicine for preventing and treating the skin superficial fungal diseases, such as dermatophyte rubrum, epidermatophyton flocculent, microsporum gypsuum and the like.
Need to check novelty before this filing date? Find Prior Art

Description

Technical field:

[0001] The invention belongs to the field of medical technology, and in particular, relates to a preparation method of Paris polyphylla saponin A, a pharmaceutical composition thereof, and applications of Paris polyphylla saponins A-D and Paris polyphylla saponin A in preparing drugs for preventing and treating superficial fungal diseases of the skin and in the field of preparing cosmetics. Background technology:

[0002] Dermatophytosis is a superficial fungal disease of the skin caused by dermatophytes such as Trichophyton rubrum, Epidermophyton floccosum and Microsporum gypseum [Xie Zhenmou, Huang Jinmei, Liu Hongfang, Zeng Weiying, Xu Qiaozhen, He Zhengqiang, Fu Bo, Xue Yaohua. Analysis of 4018 cases of superficial fungal diseases and their pathogenic bacteria. Journal of Dermatology and Venereology, 2022, 29(4): 337–341]. Dermatophytosis often has a long course of treatment, and the existing antifungal drugs are limited and have significant side effects. The development of new therapeutic drugs is of great significance for the clinical treatment of dermatophytosis [Huang Ruqi, Wang Shuang. Research progress on the anti-dermatophyte effect of traditional Chinese medicine. Chinese Journal of Endemic Disease Prevention and Control, 2020, 35(4): 432–434].

[0003] Steroidal saponins are the main chemical components of Paris L. plants, and Paris L. steroidal saponins usually have antibacterial activity [Duan Xiaoyan, Yue Meicen, Yang Jun, Bai Xue, Luo Jifeng, Li Heng, Wang Yuehu. Study on the chemical composition and antibacterial activity of the rhizomes of Paris L. Corrugated. Chinese Journal of Traditional Chinese Medicine, 2023, 48(11): 2981–2988; Yang Yingli, Bai Xue, Yang Jun, Luo Jifeng, Duan Xiaoyan, Wang Yuehu. Study on the chemical composition and antibacterial activity of the rhizomes of Paris L. Tengchong. Chinese Herbal Medicine, 2024, 55(5): 1466–1476]. However, at present, there are no reports on the antibacterial activity of Paris L. Dulong saponins A to D and Paris L. Corrugated saponin A in the prior art. Summary of the invention:

[0004] The purpose of the present invention is to provide a preparation method of a new compound, Paris polyphylla saponin A (PFV92), and use of Paris polyphylla saponins A to D and Paris polyphylla saponin A in the preparation of drugs for preventing and treating superficial fungal diseases of the skin.

[0005] In order to achieve the above-mentioned object of the present invention, the present invention provides the following technical solutions:

[0006] The compound Paris polyphylla saponin A shown in the following structural formula,

[0007]

[0008] The preparation method of the compound Paris polyphylla saponin, i.e. APFV92, comprises the following steps: taking dried Paris polyphylla rhizomes and crushing them, extracting them 3 times with 70% ethanol under reflux at 78-80°C, with the extraction time being 4h, 3h and 3h respectively, filtering to obtain a filtrate, concentrating the filtrate to obtain a crude extract, suspending the crude extract in distilled water, extracting 3 times with an equal volume of ethyl acetate, recovering the solvent from the organic phase to obtain an ethyl acetate extraction part, and continuously extracting the aqueous phase with an equal volume of n-butanol 4 times, recovering the solvent from the organic phase to obtain an n-butanol extraction part;

[0009] The n-butanol extraction part was gradient eluted by normal phase silica gel column chromatography with 200-300 meshes, and the eluent was CH2Cl2-MeOH with a ratio of 10:1 to 0:1. After the eluent was detected by thin layer chromatography, it was combined into 7 parts: Fr.I, Fr.II, Fr.III, Fr.IV, Fr.V, Fr.VI and Fr.VII. Fr.VII was gradient eluted by normal phase silica gel column chromatography with 200-300 meshes, and the eluent was EtOAc-MeOH with a ratio of 10:1 to 0:1. After the eluent was detected by thin layer chromatography, 4 parts were combined: Fr.VII-1, Fr.VII-2, Fr.VII-3 and Fr.VII-4. 10.0 g of Fr.VII-3 was taken and purified by RP C 18 Silica gel column chromatography, MeOH-H2O 10:90~100:0, was divided into 5 parts: Fr.VII-3-1, Fr.VII-3-2, Fr.VII-3-3, Fr.VII-3-4 and Fr.VII-3-5. Fr.VII-3-3 was purified by Sephadex LH-20 gel column chromatography with MeOH and then by semi-preparative HPLC, Agilent Zorbax SB-C 18 ,φ9.4×250mm;MeCN-H2O,43:57;v=2mL / min, and the Paris polyphylla saponin A, namely PFV92, was purified.

[0010] The pharmaceutical composition comprises the Paris polyphylla saponin A as an effective ingredient.

[0011] A cosmetic comprising the Paris polyphylla saponin A described in claim 1 as an active ingredient.

[0012] The application of Paris polyphylla saponin A in preparing medicine for treating superficial fungal diseases of the skin.

[0013] The application of Paris polyphylla saponin A in the preparation of cosmetics.

[0014] Use of compounds PFE52, PFE53, PFE56 and PFE59A in the preparation of drugs for treating superficial fungal diseases of the skin.

[0015] Application of compounds PFE52, PFE53, PFE56 and PFE59A in the preparation of cosmetics.

[0016] Its structural formula is as follows:

[0017]

[0018] In the present invention, when the pharmaceutical composition is used to prepare a drug, the content of the compound or its combination in the drug is preferably 0.1-99%; in the pharmaceutical composition, the content of any one of the active ingredients or any combination thereof in the pharmaceutical composition is preferably 0.5-90%. The pharmaceutical composition of the present invention is preferably used in the form of a dosage per unit body weight. In the present invention, the prepared drug can preferably be administered in two forms: injection (intravenous injection, intramuscular injection) and oral administration. The pharmaceutical preparations include tablets, capsules, nasal sprays, pills, dripping pills, etc., including but not limited to the above-mentioned preparations.

[0019] In the present invention, when compounds PFE52, PFE53, PFE56, PFE59A and PFV92 are used to prepare cosmetics, the preparation of the cosmetics is not limited and can be prepared by conventional preparation methods of cosmetics.

[0020] Compared with the prior art, the present invention has the following advantages:

[0021] 1. Compound PFV92 is a new compound.

[0022] 2. The antibacterial activities of compounds PFE52, PFE53, PFE56, PFE59A and PFV92 are reported for the first time.

[0023] 3. Compounds PFE59A and PFV92 selectively inhibited the superficial fungi Trichophyton rubrum, Epidermophyton floccosum and Microsporum gypseum.

[0024] 4. The inhibitory effects of compounds PFE52, PFE53, PFE56, PFE59A and PFV92 on 5 strains of fungi are shown in Table 2. Compounds PFE59A and PFV92 have significant inhibitory activity against the superficial infection fungi Epidermophyton floccosum, Trichophyton rubrum and Microsporum gypseum. Description of the drawings:

[0025] Figure 1 Schematic diagram of the chemical structure of Paris polyphylla saponin A (PFV92).

[0026] Figure 2Schematic diagram of the chemical structure of Dulong Paris saponins A to D.

[0027] Figure 3 Key 2D NMR correlation diagram of Paris polyphylla saponin A (PFV92). Specific implementation method:

[0028] The substantial content of the present invention is further described below with reference to the accompanying drawings using embodiments of the present invention, but the present invention is not limited thereto.

[0029] Embodiment 1:

[0030] Sources and preparation of compounds.

[0031] A total of 5 Paris polyphylla steroidal saponin compounds were tested ( Figure 1 and Figure 2 ), respectively PFE52, PFE53, PFE56, PFE59A and PFV92, and their sources or preparation methods are as follows.

[0032] 1. Preparation of PFV92.

[0033] Paris rugosa H. Li & Kurita was purchased from the Paris rugosa planting base in Shiyueliang Township, Fugong County, Yunnan Province in October 2020. The dried Paris rugosa rhizome (4.1 kg) was crushed and refluxed with 70% ethanol (50 L × 3) at 78-80 ° C for 3 times, with extraction times of 4h, 3h and 3h respectively. The filtrate was filtered and concentrated to obtain a crude extract (1.4 kg). The crude extract was suspended in 16L distilled water and extracted 3 times with an equal volume of ethyl acetate. After the organic phase was solvent recovered, the ethyl acetate extraction part (123.4 g) was obtained. The aqueous phase was further extracted 4 times with an equal volume of n-butanol. After the organic phase was solvent recovered, the n-butanol extraction part (219.3 g) was obtained.

[0034] The n-butanol extraction part (209.2 g) was subjected to gradient elution by normal phase silica gel (200-300 mesh) column chromatography, and the eluent was CH2Cl2-MeOH (10:1-0:1). After thin layer chromatography, the eluent was combined into 7 parts: Fr.I, Fr.II, Fr.III, Fr.IV, Fr.V, Fr.VI and Fr.VII. Fr.VII (162.0 g) was subjected to gradient elution by normal phase silica gel (200-300 mesh) column chromatography, and the eluent was EtOAc-MeOH (10:1-0:1). After thin layer chromatography, the eluent was combined into 4 parts: Fr.VII-1 (0.3 g), Fr.VII-2 (6.1 g), Fr.VII-3 (22.2 g) and Fr.VII-4 (112.0 g). Take 10.0g from Fr.VII-3 and pass through RP C18 Silica gel column chromatography (MeOH-H2O, 10:90-100:0) was divided into 5 parts: Fr.VII-3-1 (63.4 mg), Fr.VII-3-2 (312.3 mg), Fr.VII-3-3 (334.0 mg), Fr.VII-3-4 (56.0 mg) and Fr.VII-3-5 (7.6 g). Fr.VII-3-3 (334.0 mg) was purified by Sephadex LH-20 gel column chromatography (MeOH) and then analyzed by semi-preparative HPLC (Agilent Zorbax SB-C 18 ,φ9.4×250mm; MeCN-H2O,43:57; v=2mL / min) to purify Paris polyphylla saponin A (PFV92; 4.5mg, t R =19.4min).

[0035] 2. The origin of PFE52, PFE53, PFE56 and PFE59A.

[0036] Polyhydroxylated spirostanol saponins from the rhizomes of Paris dulongensis H. Li & Kurita were obtained by extraction and separation. The plant material was purchased from the Paris dulongensis planting base in Dulongjiang Township, Gongshan County, Yunnan Province in September 2021. The preparation method of the compound can be found in the literature [Jia J.-K., Yang J., Yang X.-Z., Luo J.-F., Duan X.-Y., Yang Y.-L., Wan J.-F., Wang Y.-H. Polyhydroxylated spirostanol saponins from the rhizomes of Paris dulongensis. Chem. Biodivers., 2024, e202400980. https: / / doi.org / 10.1002 / cbdv.202400980].

[0037] Embodiment 2:

[0038] Structural analysis of Paris polyphylla saponin A (PFV92).

[0039] Paris polyphylla saponin A (PFV92): white amorphous powder, (c 0.2, MeOH); UV(MeOH)λ max(logε)323(2.03),274(2.51),216(3.54)nm; ECD(c,0.08,MeOH)λ max (Δε)217(+10.04)nm; ESI-MS m / z 935[M+Na] + ;HR-ESI-MS m / z935.4245[M+Na] + (C 45 H 68 NaO 19 , calculated value 935.4247); 1 H and 13 C NMR data, see Table 1.

[0040] In the high-resolution electrospray ionization mass spectrometry (HR-ESI-MS) of compound PFV92, a quasi-molecular ion peak m / z 935.4245 [M+Na] can be seen. + (Calculated value C 45 H 68 NaO 19 ,935.4247), combined 13 C NMR data (Table 1), it is inferred that its molecular formula is C 45 H 68 O 19 , the unsaturation is 12. 1 H and 13 C NMR data (Table 1) show that the compound has 5 methyl groups [δ H 1.73 (3H, d, J = 6.2 Hz), 1.21 (3H, s), 1.05 (d, J = 6.8 Hz), 0.89 (3H, s), 0.67 (d, J = 5.4 Hz)], 1 disubstituted double bond [δ H 6.67(1H,d,J=8.5Hz) and 6.33(1H,d,J=8.5Hz); δ C 136.6 (CH) and 130.9 (CH)], one trisubstituted double bond [δ H 5.48(1H,dd,J=5.3,1.7Hz); δ C 144.0 (C) and 119.4 (CH)] and 3 sugars [δ H 6.39(1H,br s),5.09(1H,d,J=7.6Hz),4.80(1H,d,J=7.5Hz); δ C104.5(CH),102.1(CH),100.6(CH)]. After acid hydrolysis of compound PFV92, D-pyranose and L-pyranose rhamnose were detected. Combined with NMR data, it was determined that the structure of compound PFV92 contained two β-D-pyranose [δ H 5.09 (1H, d, J = 7.6 Hz) and 4.80 (1H, d, J = 7.5 Hz)] and 1 α-L-rhamnose [δ H 6.39 (1H, br s)]. By comparing with the NMR data of Parisvanioside A [Yan H., Ni W., Yu L.-L., Xiao L.-G., Ji Y.-H., Liu H.-Y. Parisvaniosides A–E, five new steroidal saponins from Parisvaniotii. Steroids, 2022, 177: 108949], it was speculated that compound PFV92 was a steroidal saponin with the same aglycone.

[0041] according to 1 H- 1 H COSY correlation ( Figure 3 ), fragments a(H-1 / H2-2 / H-3 / H2-4), b(H-6 / H-7), c(H-11 / H2-12), d(H-14 / H2-15 / H-16 / H-17 / H-20 / H3-21), e[H2-23 / H2-24 / H-25 / (H2-26) / H3-27], f(H-1′ / H-2′ / H-3′ / H-4′ / H-5′ / H2-6′), g(H-1″ / H-2″ / H-3″ / H-4″ / H-5″ / H3-6″) and h(H-1″′ / H-2″′ / H-3″′ / H-4″′ / H-5″′ / H2-6″′) can be deduced. In the HMBC correlation spectrum ( Figure 3 ), we can see that H3-19 is related to C-1, C-5, C-9 and C-10, H2-4 is related to C-10, H-6 is related to C-4 and C-10, H-7 is related to C-9, H3-18 is related to C-12, C-13, C-14 and C-17, and H3-21 and H2-26 are related to C-22, indicating that the double bond is located at C-6; H2-15 is related to C-8, and H3-19 is related to C-5, indicating that C-5 and C-8 are oxidized. In the ROESY correlation spectrum ( Figure 3), we can see that H-1β / H3-19, H3-19 / H-6, H-7 / H3-18, H3-18 / H-20, H-20 / H2-23 and H3-27 / H2-26 are correlated, indicating that these hydrogen atoms are in the same plane. Assuming the β orientation, the orientation of the peroxide bridge and H-17 is α orientation; the correlation of H-17 / H-14, H-14 / H-16 and H-1α / H-3 indicates that these hydrogen atoms are α orientation, and H-26 is α orientation. ax / H3-27 and H-26 eq / H3-27 correlation, indicating that 25-Me is located on the flat bond of the six-membered ring chair conformation, thus confirming that the aglycone of compound PFV92 is (25R)-Spirost-6,11-diene-5α,8α-epidioxy-3β-ol. According to the HMBC correlation of H-3 with C-1′, H-1′ with C-3, H-2′ with C-1″, H-1″ with C-2′, H-3′ with C-1″′, and H-1″′ with C-3′, it shows that β-D-pyranose glucose [4.80 (1H, d, J=7.5Hz)] is located at C-3, β-D-pyranose glucose [δ H 5.09 (1H, d, J = 7.6 Hz) at C-2′, α-L-rhamnose [δ H 6.39 (1H, br s)] is located at C-3′, therefore, the sugar chain was determined to be α-L-rhamnopyranosyl-(1→2)-O-[β-D-glucopyranosyl-(1→3)]-β-D-glucopyranosyl, located on the 3-OH of the aglycone. Therefore, the chemical structure of PFV92 was determined to be (25R)-Spirost-6,11-diene-5α,8α-epidioxy-3β-ol3-α-L-rhamnopyranosyl-(1→2)-O-[β-D-glucopyranosyl-(1→3)]-β-D-glu copyranoside, named rugosaroside A.

[0042] Table 1 PFV92 in deuterated pyridine 1 H(500MHz) and 13 C (126MHz) NMR data (δ in ppm, J in Hz)

[0043]

[0044] Embodiment 3:

[0045] The antidermatophyte activity test method is as follows:

[0046] Epidermophyton floccosum CBS 566.94, Trichophyton rubrum ATCC4438, and Microsporum gypseum CBS118893 were purchased from the Chinese Academy of Medical Sciences Medical Fungi Collection Center; Candida albicans ATCC10231 was purchased from Microbiologics, Inc., USA; and the fluconazole-resistant strain of Candida albicans was donated by the Department of Dermatology, the First Affiliated Hospital of Kunming Medical College.

[0047] Terbinafine hydrochloride and DMSO were purchased from Sigma; agar powder and chloramphenicol were purchased from Scientific Research Special.

[0048] Take a 96-well culture plate, dilute the sample to be tested, add fungal liquid to each well, and the final concentration is 5×10 5 CFU / mL, cultured at 25℃ for 5 days, and the absorbance at 625nm was detected by microplate reader. The experiment also set up medium blank control, fungal control and positive drug control.

[0049] Embodiment 4:

[0050] The inhibitory effects of compounds PFE52, PFE53, PFE56, PFE59A and PFV92 on 5 fungi are shown in Table 2. Compounds PFE59A and PFV92 have significant inhibitory activity against Epidermophyton floccosum, Trichophyton rubrum and Microsporum gypseum, which are superficial infection fungi, but have no inhibitory effect on Candida albicans and fluconazole-resistant strains of Candida albicans, which are deep infection fungi.

[0051] Table 2 Inhibitory effects of compounds on 5 fungi

[0052]

[0053] *Positive control

[0054] Embodiment 5:

[0055] Take any one or any several of Paris polyphylla saponin A (PFV92), Paris polyphylla saponin B (PFE52), Paris polyphylla saponin A (PFE53), Paris polyphylla saponin D (PFE56), Paris polyphylla saponin C (PFE59A), add excipients in a weight ratio of 1:1 to the excipients, and granulate and tablet.

[0056] Embodiment 6:

[0057] Take any one or any several of Paris polyphylla saponin A (PFV92), Paris polyphylla saponin B (PFE52), Paris polyphylla saponin A (PFE53), Paris polyphylla saponin D (PFE56), Paris polyphylla saponin C (PFE59A), add excipients in a weight ratio of 1:2 to the excipients, and granulate and tablet.

[0058] Embodiment 7:

[0059] Take any one or any several of Paris polyphylla saponin A (PFV92), Paris polyphylla saponin B (PFE52), Paris polyphylla saponin A (PFE53), Paris polyphylla saponin D (PFE56), Paris polyphylla saponin C (PFE59A), and prepare capsules according to conventional capsule preparation method.

[0060] Embodiment 8:

[0061] Tablets were prepared as follows

[0062] Tablets: Paris polyphylla saponin A (PFV92), Paris polyphylla saponin B (PFE52), Paris polyphylla saponin A (PFE53), Paris polyphylla saponin D (PFE56), Paris polyphylla saponin C (PFE59A)

[0063] Embodiment 9:

[0064] Capsules: 100 mg of any one or any combination of Paris polyphylla saponin A (PFV92), Paris polyphylla saponin B (PFE52), Paris polyphylla saponin A (PFE53), Paris polyphylla saponin D (PFE56), Paris polyphylla saponin C (PFE59A)

[0065] Starch amount

[0066] Magnesium stearate appropriate amount

[0067] Preparation method: Mix any one or any several of Paris polyphylla saponin A (PFV92), Paris polyphylla saponin B (PFE52), Paris polyphylla saponin A (PFE53), Paris polyphylla saponin D (PFE56), Paris polyphylla saponin C (PFE59A) with auxiliary agents, sieve, mix evenly in a suitable container, and put the obtained mixture into hard gelatin capsules.

[0068] Embodiment 10:

[0069] Nasal spray: Paris polyphylla saponin A (PFV92), Paris polyphylla saponin B (PFE52), Paris polyphylla saponin A (PFE53), Paris polyphylla saponin D (PFE56), Paris polyphylla saponin C (PFE59A)

[0070] Preparation: Add one ingredient at a time to an appropriate volume of double distilled water under stirring until completely dissolved, then add another ingredient. After adding water to 2 ml, filter the solution on a sterile filter, fill it into bottles and divide it according to appropriate dosages.

[0071] Embodiment 11

[0072] Spray: Take any one or any of Paris polyphylla saponin A (PFV92), Paris polyphylla saponin B (PFE52), Paris polyphylla saponin A (PFE53), Paris polyphylla saponin D (PFE56), Paris polyphylla saponin C (PFE59A), soak in water for 4 hours, perform steam distillation, collect aromatic water 4 times the amount of the medicinal material, perform secondary distillation, collect aromatic water 1.5 times the amount of the medicinal material, then add peppermint oil and Tween-80, shake thoroughly to clarify, filter, and potting to obtain. For external use.

[0073] Or, take any one or any several of Paris polyphylla saponin A (PFV92), Paris polyphylla saponin B (PFE52), Paris polyphylla saponin A (PFE53), Paris polyphylla saponin D (PFE56), Paris polyphylla saponin C (PFE59A), and obtain a spray according to a conventional spray preparation method for external use.

[0074] Embodiment 12:

[0075] Drop pills: 1g of any one or any combination of Paris polyphylla saponin A (PFV92), Paris polyphylla saponin B (PFE52), Paris polyphylla saponin A (PFE53), Paris polyphylla saponin D (PFE56), Paris polyphylla saponin C (PFE59A)

[0076] Macrogol 6000 9g

[0077] Preparation method: Preparation of 6000 molten liquid: weigh any one or any several of Paris polyphylla saponin A (PFV92), Paris polyphylla saponin B (PFE52), Paris polyphylla saponin A (PFE53), Paris polyphylla saponin D (PFE56), Paris polyphylla saponin C (PFE59A) according to the above prescription amount, add appropriate amount of anhydrous ethanol, dissolve with slight heat, add to the prescribed amount of polyethylene glycol molten liquid (keep warm in a 60°C water bath), stir and mix evenly until the ethanol is evaporated, keep it in a 60°C water bath for 30 minutes, wait for all bubbles to be removed, then transfer the mixed molten liquid with all bubbles removed into a liquid storage cylinder, keep it warm at 80-85°C, control the dripping speed, drip it drop by drop into the condensate, wait for the condensation to be completely condensed, pour off the condensate, collect the pellets, drain and remove the condensate on the pellets with filter paper, place them in a silica gel desiccator or dry them naturally.

[0078] Embodiment 13:

[0079] Tablets: 10 mg of any one or any combination of Paris polyphylla saponin A (PFV92), Paris polyphylla saponin B (PFE52), Paris polyphylla saponin A (PFE53), Paris polyphylla saponin D (PFE56), Paris polyphylla saponin C (PFE59A), lactose 180 mg, starch 55 mg, magnesium stearate 5 mg;

[0080] Preparation method: Mix any one or any several of Paris polyphylla saponin A (PFV92), Paris polyphylla saponin B (PFE52), Paris polyphylla saponin A (PFE53), Paris polyphylla saponin D (PFE56), Paris polyphylla saponin C (PFE59A), lactose and starch, and evenly moisten them with water. Sieve and dry the moistened mixture, sieve again, add magnesium stearate, and then compress the mixture into tablets. Each tablet weighs 250 mg and contains 10 mg of the compound.

[0081] Embodiment 14:

[0082] Ampoule: 2 mg of any one or any combination of Paris polyphylla saponin A (PFV92), Paris polyphylla saponin B (PFE52), Paris polyphylla saponin A (PFE53), Paris polyphylla saponin D (PFE56), Paris polyphylla saponin C (PFE59A), and 10 mg of sodium chloride;

[0083] Preparation method: dissolve any one or several of Paris polyphylla saponin A (PFV92), Paris polyphylla saponin B (PFE52), Paris polyphylla saponin A (PFE53), Paris polyphylla saponin D (PFE56), Paris polyphylla saponin C (PFE59A), and sodium chloride in an appropriate amount of water for injection, filter the resulting solution, and fill it into an ampoule under sterile conditions.

[0084] Embodiment 15:

[0085] Capsules: 10 mg of any one or any combination of Paris polyphylla saponin A (PFV92), Paris polyphylla saponin B (PFE52), Paris polyphylla saponin A (PFE53), Paris polyphylla saponin D (PFE56), Paris polyphylla saponin C (PFE59A), lactose 187 mg, magnesium stearate 3 mg;

[0086] Preparation method: Mix any one or any several of Paris polyphylla saponin A (PFV92), Paris polyphylla saponin B (PFE52), Paris polyphylla saponin A (PFE53), Paris polyphylla saponin D (PFE56), Paris polyphylla saponin C (PFE59A) with auxiliary agents, sieve, mix evenly, and put the obtained mixture into hard gelatin capsules, each capsule weighing 200 mg and containing 10 mg of active ingredient.

[0087] Embodiment 16:

[0088] Ointment: Heat the oily substance (such as vaseline, stearic acid) to about 80 degrees to melt, and filter it with fine cloth; dissolve the water-soluble ingredients (such as borax, sodium hydroxide, triethanolamine, lauryl sulfuric acid, moisturizer, preservative, etc.) in water, and add the water-soluble phase to the oil phase slowly when the temperature is slightly higher than that of the oil phase, stirring while adding to make an emulsion matrix. Add the drug according to any one or any combination of Paris polyphylla saponin A (PFV92), Paris polyphylla saponin B (PFE52), Paris polyphylla saponin A (PFE53), Paris polyphylla saponin D (PFE56), Paris polyphylla saponin C (PFE59A), and stir until condensed. For external use.

[0089] Or, take any one or any several of Paris polyphylla saponin A (PFV92), Paris polyphylla saponin B (PFE52), Paris polyphylla saponin A (PFE53), Paris polyphylla saponin D (PFE56), Paris polyphylla saponin C (PFE59A), and obtain an ointment according to a conventional ointment preparation method for external use.

[0090] Embodiment 17:

[0091] Cream formula containing any one or any combination of Paris polyphylla saponin A (PFV92), Paris polyphylla saponin B (PFE52), Paris polyphylla saponin A (PFE53), Paris polyphylla saponin D (PFE56), Paris polyphylla saponin C (PFE59A):

[0092] According to Paris polyphylla saponin A (PFV92), Paris polyphylla saponin B (PFE52), Paris polyphylla saponin A (PFE53), Paris polyphylla saponin D (PFE56), Paris polyphylla saponin C (PFE59A)

[0093] The cosmetics of the present invention are prepared by conventional methods for preparing cosmetics.

[0094] Embodiment 18:

[0095] Emulsion formula containing any one or any combination of Paris polyphylla saponin A (PFV92), Paris polyphylla saponin B (PFE52), Paris polyphylla saponin A (PFE53), Paris polyphylla saponin D (PFE56), Paris polyphylla saponin C (PFE59A):

[0096] According to Paris polyphylla saponin A (PFV92), Paris polyphylla saponin B (PFE52), Paris polyphylla saponin A (PFE53), Paris polyphylla saponin D (PFE56), Paris polyphylla saponin C (PFE59A)

[0097]

[0098] The cosmetics of the present invention are prepared by conventional methods for preparing cosmetics.

Claims

1. The compound Paris polyphylla saponin A shown in the following structural formula, 2. A method for preparing the compound Paris polyphylla saponin APFV92 according to claim 1, It is characterized in that The method comprises the following steps: taking dried Paris polyphylla rhizome and crushing it, extracting it three times with 70% ethanol under reflux at 78-80 DEG C, the extraction time being 4 hours, 3 hours and 3 hours respectively, filtering to obtain a filtrate, concentrating the filtrate to obtain a crude extract, suspending the crude extract in distilled water, extracting it three times with an equal volume of ethyl acetate, recovering the solvent from the organic phase to obtain an ethyl acetate extraction part, continuously extracting the aqueous phase with an equal volume of n-butanol for four times, recovering the solvent from the organic phase to obtain an n-butanol extraction part; The n-butanol extraction part was gradient eluted using a 200-300 mesh normal phase silica gel column chromatography, and the eluent was 10:1-0:1 CH 2 Cl 2 -MeOH, the eluate was detected by thin layer chromatography and combined into 7 parts: Fr.I, Fr.II, Fr.III, Fr.IV, Fr.V, Fr.VI and Fr.VII. Fr.VII was gradient eluted with 200-300 mesh normal phase silica gel column chromatography, and the eluent was 10:1-0:1 EtOAc-MeOH. After the eluate was detected by thin layer chromatography, 4 parts were combined: Fr.VII-1, Fr.VII-2, Fr.VII-3 and Fr.VII-4. 10.0 g of Fr.VII-3 was taken and RP C 18 Silica gel column chromatography, MeOH-H 2 O 10:90~100:0, divided into 5 parts: Fr.VII-3-1, Fr.VII-3-2, Fr.VII-3-3, Fr.VII-3-4 and Fr.VII-3-5. Fr.VII-3-3 was purified by Sephadex LH-20 gel column chromatography with MeOH and then purified by semi-preparative HPLC, Agilent Zorbax SB-C 18 ,φ9.4×250mm;MeCN-H 2 O, 43:57; v = 2mL / min, and the Paris polyphylla saponin A, namely PFV92, was purified.

3. Pharmaceutical composition, Features: The effective ingredient is the Paris polyphylla saponin A described in claim 1.

4. Cosmetics, Features: The effective ingredient is the Paris polyphylla saponin A described in claim 1.

5. Use of the Paris polyphylla saponin A described in claim 1 in the preparation of a medicament for treating superficial fungal diseases of the skin.

6. Use of the Paris polyphylla saponin A described in claim 1 in the preparation of cosmetics.

7. Use of compounds PFE52, PFE53, PFE56 and PFE59A shown in the following structural formula in the preparation of drugs for treating superficial fungal diseases of the skin:

8. Use of compounds PFE52, PFE53, PFE56 and PFE59A shown in the following structural formula in the preparation of cosmetics:

Citation Information

Patent Citations

  • Application of polyphyllin in preparation of anti-candida albicans fluconazole drug-resistant strain product and anti-dermatophyte product

    CN114432326A

  • Application of polyphyllin in preparation of anti-dermatophyte product

    CN116440149A

  • Steroid sapogenin compounds and process for their production

    US2977358A